General contact information for trials in Alberta:
- Alberta Cancer Clinical Trials – acb.acct@albertahealthservices.ca
- Edmonton: Cross Cancer Institute (780-432-8771)
- Calgary: Tom Baker Cancer Centre (403-521-3723)
NO LONGER Recruiting – Active Trial Locations in Alberta:
ID Number: NCT03465722
Links:
Description: This study looks at the drug Avapritnib (BLU-285) for patients with advanced or metastatic a Gastrointestinal Stromal Tumor (GIST) compared to Regorafenib. Patients will take one of the two study drugs over 2 months and the researchers will compare their survival and disease status over time to decide which medication is more effective.
Intervention: Both of the drugs being compared in this study are meant to stop cancer cells from spreading. Regorafenib is a kinase inhibitor. This means that it stops cancer cells from producing certain proteins they need to survive and divide. It is widely used to treat various types of cancer. Avapritnib looks like a promising new treatment which can stop cancer cells from dividing. This trial will help to figure out if it is helpful in treating a specific type of gastric cancer.
Can I consider participating?
Recruiting location in Alberta:
ID Number: NCT02935634
Link:
Description: This study is trying to understand the best way to use the drug Nivolumab in a combination with other immunotherapeutic treatments in patients with advanced gastric cancer. There will be three groups in this trial. Each one will compare a different combination of medication:
Intervention:
Can I consider participating?
NO LONGER recruiting – Active Trial Locations in Alberta:
ID Number: NCT02554812
Link:
Description: This is a Phase II trial. It is looking at the effects of the drug Avelumab combined with other cancer therapies for treating advanced gastric tumors. There are many treatment groups in this trial, because the researchers are interested in testing various dosages of each drug, as well as different combinations. The drug combinations they will be testing are:
Intervention: All of the medications involved in this trial are immunotherapeutic. They help our immune system’s T cells recognize and attack tumor cells. This trial is trying to understand the effects of the drugs in combination with each other, as well as determine the appropriate dose for each medication.
Can I consider participating?
ACTIVE, no longer recruiting:
ID Number: NCT03000257
Link:
Description: This study is looking at the dosage and safety of drug ABBV-181 on its own and in combination with rovalpituzumab tesirine and venetoclax. The study will consist of 3 parts:
A: ABBV-181
B: ABBV-181 and rovalpituzumab tesirine
C: ABBV-181 and venetoclax
Intervention:Venetoclax is a chemotherapy drug, which means it attack cancerous cells. Rovalpituzumab tesirine and ABBV-181 are immunotherapy drugs. Immunotherapy drugs help the immune cells target and get rid of cancerous cells.
Can I consider participating?